Metastatic melanoma: Chemotherapy

Cancer: Principles and Practice of Oncology.

1991 • 8,402 citations

Angiogenesis in cancer, vascular, rheumatoid and other disease

1995 • 7,717 citations

Cancer statistics, 1999

1999 • 3,154 citations

Thalidomide is an inhibitor of angiogenesis.

1994 • 2,460 citations

Interleukin-12: A Proinflammatory Cytokine with Immunoregulatory Functions that Bridge Innate Resistance and Antigen-Specific Adaptive Immunity

1995 • 2,437 citations

High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

1999 • 1,967 citations

Interleukin-10

1993 • 1,820 citations

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

2000 • 1,252 citations

Treatment of 283 Consecutive Patients With Metastatic Melanoma or Renal Cell Cancer Using High-Dose Bolus Interleukin 2

1994 • 1,070 citations

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

1999 • 1,044 citations

Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients

1989 • 1,003 citations

A Southwest Oncology Group study

1993 • 778 citations

Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma

1999 • 756 citations

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1985 • 737 citations

Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

1997 • 556 citations

High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.

2000 • 500 citations

Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2

1998 • 480 citations

Biologic Therapy of Cancer

1992 • 476 citations

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.

2001 • 421 citations

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.

1987 • 386 citations

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.

1989 • 383 citations

Sequential Biochemotherapy Versus Chemotherapy for Metastatic Melanoma: Results From a Phase III Randomized Trial

2002 • 378 citations

Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2b

1999 • 318 citations

Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule.

1999 • 317 citations

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.

1998 • 309 citations

Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic Melanoma

2001 • 308 citations

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

1998 • 298 citations

Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.

1995 • 290 citations

Sequential chemoimmunotherapy in the treatment of metastatic melanoma.

1992 • 258 citations

Final report of the french multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases

1990 • 243 citations

Treatment of Metastatic Malignant Melanoma with Dacarbazine plus Tamoxifen

1992 • 241 citations

Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma.

1984 • 234 citations

Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism.

1996 • 227 citations

Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice.

1996 • 207 citations

Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.

1991 • 200 citations

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.

1997 • 197 citations

WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.

1987 • 197 citations

Drug-resistance in human melanoma

2001 • 185 citations

A phase II study of taxol in patients with malignant melanoma

1991 • 179 citations

A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma

1989 • 179 citations

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.

1996 • 176 citations

Guidelines for the Safe Administration of High-Dose Interleukin-2

2001 • 174 citations

Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma IV. Late results after complete response to chemotherapy (central oncology group protocols 7130, 7131, and 7131A)

1984 • 169 citations

Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma.

1998 • 160 citations

Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.

1994 • 153 citations

Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials

2001 • 153 citations

Systemic treatments for advanced cutaneous melanoma.

1995 • 145 citations

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.

1994 • 131 citations

Cisplatin, Dacarbazine With or Without Subcutaneous Interleukin-2, and Interferon Alfa-2b in Advanced Melanoma Outpatients: Results From an Italian Multicenter Phase III Randomized Clinical Trial

2002 • 124 citations

The treatment of metastatic melanoma with chemotherapy and biologies

1997 • 124 citations

A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.

2002 • 109 citations

DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma

1980 • 102 citations

Combination of Chemotherapy With Interleukin-2 and Interferon Alfa for the Treatment of Metastatic Melanoma

1999 • 102 citations

Advantages of Concurrent Biochemotherapy Modified by Decrescendo Interleukin-2, Granulocyte Colony-Stimulating Factor, and Tamoxifen for Patients With Metastatic Melanoma

1999 • 97 citations

Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.

1995 • 96 citations

Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study.

1991 • 93 citations

Interferons in melanoma

1996 • 80 citations

In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines

1997 • 76 citations

Phase III Clinical Trial of the Combination of Cisplatin, Dacarbazine, and Carmustine With or Without Tamoxifen in Patients With Advanced Malignant Melanoma

1999 • 74 citations

A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma

1993 • 72 citations

Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-α after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen

1995 • 71 citations

Phase II trial of carboplatin in advanced malignant melanoma.

1987 • 71 citations

Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-?-2a in patients with metastatic melanoma

1999 • 71 citations

A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.

1999 • 68 citations

Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG)

1995 • 62 citations

Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up

1995 • 62 citations

Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study.

1984 • 51 citations

Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma

1988 • 50 citations

Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway

2000 • 48 citations

Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma.

1993 • 48 citations

Activity and unexpected lung toxicity of the sequential administration of two alkylating agents—Dacarbazine and fotemustine—in patients with melanoma

1993 • 45 citations

Paclitaxel and tamoxifen

2000 • 45 citations

IMMUNOTHERAPY AND EXPERIMENTAL APPROACHES FOR METASTATIC MELANOMA

1998 • 43 citations

Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma

1991 • 42 citations

Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma

1993 • 40 citations

Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration.

1991 • 39 citations

Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine-resistant melanoma patients

2001 • 35 citations

Taxol and vinorelbine: a new active combination for disseminated malignant melanoma

1996 • 33 citations

Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma—an effective combination with unexpected toxicity

1992 • 33 citations

The Emerging Role of Cytokines in the Treatment of Advanced Melanoma

2000 • 33 citations

Positive phase II study in the treatment of advanced malignant melanoma with fotemustine

1991 • 33 citations

Interferon-α and chemohormonal therapy for patients with advanced melanoma

1998 • 29 citations

Bryostatin-1 and IL-2 Synergize to Induce IFN-γ Expression in Human Peripheral Blood T Cells: Implications for Cancer Immunotherapy

2001 • 28 citations

Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.

1997 • 27 citations

Daily Low-Dose Subcutaneous Recombinant Interleukin-2 by Alternate Weekly Administration

1998 • 23 citations

Cisplatin, dacarbazine, and fotemustine plus interferon α in patients with advanced malignant melanoma

2000 • 23 citations

Fotemustine plus dacarbazine for malignant melanoma

1992 • 23 citations

A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma

2000 • 21 citations

Phase II Trial of Pyrazoloacridine in Children With Solid Tumors: A Pediatric Oncology Group Phase II Study

2000 • 19 citations

A phase II study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma

2001 • 19 citations

A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma

2000 • 17 citations

Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen)

1990 • 16 citations

The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program.

2000 • 15 citations

Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma

1998 • 15 citations

Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma

1995 • 15 citations

Low-dose integrated chemoimmunohormonotherapy with cisplatin, subcutaneous interleukin-2, interferon and tamoxifen for advanced metastatic melanoma???a pilot study

1996 • 15 citations

Future directions for temozolomide therapy

2001 • 15 citations

Chemotherapy of metastatic melanoma.

1992 • 15 citations

Local treatment of cutaneous and subcutaneous metastatic malignant melanoma with fotemustine

1991 • 14 citations

Fotemustine and dacarbazine plus recombinant interferon alpha2a in the treatment of advanced melanoma

1997 • 13 citations

Long-term outcome of treatment with dacarbazine, cisplatin, interferon-α and intravenous high dose interleukin-2 in poor risk melanoma patients

1998 • 12 citations

Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine

1998 • 11 citations

A Feasibility Study using Polychemotherapy (Cisplatin + Vindesine + Dacarbazine) plus Interferon-Alpha or Monochemotherapy with Dacarbazine plus Interferon-Alpha in Metastatic Melanoma

2001 • 11 citations

Fotemustine and interferon à2b in metastatic malignant melanoma

1998 • 10 citations

Cytarabine and cisplatin in advanced malignant melanoma.

1986 • 9 citations

Phase II Trial of Piritrexim and DTIC Using an Alternating Dose Schedule in Metastatic Melanoma

1995 • 7 citations

Preliminary Experience with High-Dose Cisplatin, Reduced Glutathione and Natural Interferon-α in Dacarbazine-Resistant Malignant Melanoma

1998 • 7 citations

Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma

1998 • 7 citations

Combined Carboplatin and Cytosine Arabinoside in Metastatic Melanoma Refractory to Dacarbazine

1995 • 6 citations

Melanoma therapy

1992 • 5 citations

Subcutaneous interleukin-2 and interferon-alpha therapy associated with cisplatin monochemotherapy in the treatment of metastatic melanoma.

1998 • 2 citations

Interleukin-2 for anti-cancer therapy.

1991 • 2 citations

Deleted Work

1955 • 0 citations